Browsing Category
Pharma Industry News
4720 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
Pfizer (PFE), Merck (MRK) win FDA expansion for Padcev plus Keytruda in all MIBC patients
Pfizer (PFE) Padcev+Keytruda MIBC label expands to all patients as first platinum-free regimen; AstraZeneca's Imfinzi cisplatin-only slot loses ground.
Scancell Holdings (LSE:SCLP): Can a Nasdaq deal fund its pivotal melanoma trial?
Scancell has strong melanoma data, but Phase 3 still needs funding. A Nasdaq deal could reset LSE:SCLP, or leave investors facing dilution and deal risk.
ImmuPharma (LSE: IMM) has two biotech catalysts, but can P140 finally deliver the deal?
ImmuPharma targets a P140 licensing deal while LSE trades below its Lanstead benchmark. The next partner decision could reshape the biotech story.
Avacta (AIM: AVCT) just paid down ÂŁ3.67m of bond debt in cash. The real question is what AVA6103 does next.
Avacta cleared bond debt in cash and reaches its AVA6103 readout on funded runway. The next six months decide whether pre|CISION reads as one drug or a platform.
Rhythm Pharmaceuticals (RYTM) TRANSCEND trial in NEJM shows 19.8% placebo-adjusted BMI reduction
Rhythm Pharma (RYTM) TRANSCEND Phase 3 published in NEJM validates IMCIVREE for acquired hypothalamic obesity. 10,000-patient US market launch trajectory ahead.
Mesoblast stock gains as Ryoncil revenue hits US$115m in first launch year
Mesoblast Ryoncil revenue hits US$115m in its first launch year. Read how ASX:MSB’s biotech story is shifting from promise to sales.
Ionis Pharmaceuticals (IONS) drops 21% as Wainua Phase 3 ATTR-CM trial fails, Alnylam Amvuttra and BridgeBio Attruby emerge as clear beneficiaries
Ionis (IONS) drops 21% as Wainua Phase 3 ATTR-CM trial fails primary endpoint. Peak sales cut to $4B. Alnylam and BridgeBio benefit from the reset.
AstraZeneca (AZN) shares fall as Wainua Phase III trial miss dents ATTR-CM growth hopes
Read how AstraZeneca’s Wainua trial miss reshapes AZN stock sentiment, ATTR-CM competition and its 2030 growth story after July 9.
Everest Medicines closes $1.14bn Travere deal for rare kidney disease drug
Everest Medicines closes its $1.14 billion Travere deal for civorebrutinib. Read how the BTK licence reshapes 1952.HK, TVTX and rare kidney strategy.
Aligos receives $25m Amoytop payment as China HBV catalyst strengthens
Aligos receives $25 million from Amoytop as China grants breakthrough status to its HBV drug. Read how the deal reshapes ALGS cash runway and strategy.